406
Chapter 11
196. De Potter CR, Foschini MP, Schelfhout A-M,et al. Immunohisto-
chemical study of neu protein overexpression in clinging
in situ
duct
carcinoma of the breast.
Virchows Arch [A]
1993;422:375–380.
197. Sek P, Zawrocki A, Biernat W, et al. HER2 molecular subtype is a
dominant subtype of mammary Paget’s cells. An immunohistochemi-
cal study.
Histopathology
2010;57:564–571.
198. Rudas M, Neumayer R, Gnant MFX, et al. p53 protein expression, cell
proliferation and steroid hormone receptors in ductal and lobular
in
situ
carcinomas of the breast.
Eur J Cancer
1997;33:39–44.
199. Isola JJ, Holli K, Oksa H, et al. Elevated erbB-2 oncoprotein levels in
preoperative and follow-up serum samples define an aggressive dis-
ease course in patients with breast cancer.
Cancer
1994;73:652–658.
200. Esteva-Lorenzo FJ, Paik S, Harris LN. Serum erbB-2 in ductal carci-
noma
in situ
of the breast—a marker of microinvasion.
Acta Oncol
1997;36:651–652.
201. Volas GH, Leitzel K, Teramoto Y, et al. Serial serum c-erbB-2 levels in
patients with breast carcinoma.
Cancer
1996;78:267–272.
202. Livasy CA, Perou CM, Karaca G, et al. Identification of a basal-like
subtype of ductal carcinoma
in situ
.
Hum Pathol
2007;38:197–204.
203. Thike AA, Iqbal J, Cheok PY, et al. Ductal carcinoma
in situ
associated
with triple negative invasive breast cancer: evidence for a precursor–
product relationship.
J Clin Pathol
2013;66:665–670.
204. O’Malley FP, Vnencak-Jones CL, Dupont WD, et al. p53 mutations are
confined to the comedo type ductal carcinoma
in situ
of the breast. Im-
munohistochemical and sequencing data.
Lab Invest
1994;71:67–72.
205. Rajan PB, Scott DJ, Perry RH, et al. p53 protein expression in duc-
tal carcinoma
in situ
(DCIS) of the breast.
Breast Cancer Res Treat
1997;42:283–290.
206. Poller DN, Bell RJA, Elston CW, et al. p53 protein expression in mam-
mary ductal carcinoma
in situ
: relationship to immunohistochemical
expression of estrogen receptor and c-erbB-2 protein.
Hum Pathol
1993;24:463–468.
207. Leal CB, Schmitt FC, Bento MJ, et al. Ductal carcinoma
in situ
of the
breast. Histologic categorization and its relationship to ploidy and
immunohistochemical expression of hormone receptors, p53 and
c-erbB-2 protein.
Cancer
1995;75:2123–2131.
208. Done SJ, Arneson NCR, Ozcelik H, et al. p53 mutations in mammary
ductal carcinoma
in situ
but not in epithelial hyperplasia.
Cancer Res
1998;58:785–789.
209. Walker RA, Dearing SJ, Lane DP, et al. Expression of p53 protein in
infiltrating and
in-situ
breast carcinomas.
J Pathol
1991;165:203–211.
210. Barnes R, Masood S, Barker E, et al. Low nm23 protein expression in
infiltrating ductal breast carcinomas correlates with reduced patient
survival.
Am J Pathol
1991;139:245–250.
211. Simpson JF, O’Malley F, Dupont WD, et al. Heterogeneous expres-
sion of nm23 gene product in noninvasive breast carcinoma.
Cancer
1994;73:2352–2358.
212. Vos CB, Cleton-Jansen AM, Berx G, et al. E-Cadherin inactivation in
lobular carcinoma
in situ
of the breast: an early event in tumorigen-
esis.
Br J Cancer
1997;76:1131–1133.
213. Gupta SK, Douglas-Jones AG, Jasani B, et al. E-Cadherin (E-cad) ex-
pression in duct carcinoma
in situ
(DCIS) of the breast.
Virchows Arch
1997;430:23–28.
214. Bankfalvi A, Terpe HJ, Breukelmann D, et al. Immunophenotypic and
prognostic analysis of E-cadherin and beta-catenin expression during
breast carcinogenesis and tumour progression: a comparative study
with CD44.
Histopathology
1999;34:25–34.
215. Aasmundstad TA, Haugen OA. DNA ploidy in intraductal breast car-
cinomas.
Eur J Cancer
1990;26:956–959.
216. Crissman JD, Visscher DW, Kubus J. Image cytophotometric DNA
analysis of atypical hyperplasias and intraductal carcinomas of the
breast.
Arch Pathol Lab Med
1990;114:1239–1253.
217. Killeen JL, Namiki H. DNA analysis of ductal carcinoma
in situ
of the breast. A comparison with histologic features.
Cancer
1991;68:2602–2607.
218. Locker AP, Horrocks C, Gilmour AS, et al. Flow cytometric and his-
tological analysis of ductal carcinoma
in situ
of the breast.
Br J Surg
1990;77:564–567.
219. Pallis L, Skoog L, Falkmer U, et al. The DNA profile of breast cancer
in
situ
.
Eur J Surg Oncol
1992;18:108–111.
220. Sataloff DM, Russin Vl, Sohn M, et al. DNA flow cytometric analysis
in ductal carcinoma
in situ
of the breast.
Breast Dis
1993;6:195–205.
221. MeyerJE,KopansDB,StomperPC,etal.Occultbreastabnormalities:per-
cutaneous preoperative needle localization.
Radiology
1984;150:335–337.
172. Guidi AJ, Schnitt SJ, Fischer L, et al. Vascular permeability fac-
tor (vascular endothelial growth factor) expression and angiogen-
esis in patients with ductal carcinoma
in situ
of the breast.
Cancer
1997;80:1945–1953.
173. Carpenter PM, ChenWP, Mendez A, et al. Angiogenesis in the progres-
sion of breast ductal proliferations.
Int J Surg Pathol
2011;19:335–341.
174. Adler EH, Sunkara JL, Patchefsky AS, et al. Predictors of disease pro-
gression in ductal carcinoma
in situ
of the breast and vascular pat-
terns.
Hum Pathol
2012;43:550–556.
175. Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast
recurrence: a systematic review.
J Cancer
2011;2:232–261.
176. Hammond ME, Hayes DF, Dowsett M, et al. American Society of
Clinical Oncology/College of American Pathologists guideline recom-
mendations for immunohistochemical testing of estrogen and proges-
terone receptors in breast cancer.
J Clin Oncol
2010;28:2784–2795.
177. Lesser ML, Rosen PP, Senie RT, et al. Estrogen and progesterone re-
ceptors in breast carcinoma: correlations with epidemiology and pa-
thology.
Cancer
1981;48:299–309.
178. Barnes R, Masood S. Potential value of hormone receptor assay in car-
cinoma
in situ
of breast.
Am J Clin Pathol
1990;94:533–537.
179. Bur ME, Zimarowski MJ, Schnitt SJ, et al. Estrogen receptor im-
munohistochemistry in carcinoma
in situ
of the breast.
Cancer
1992;69:1174–1181.
180. Holland PA, Knox WF, Potten CS, et al. Assessment of hormone de-
pendence of comedo ductal carcinoma
in situ
of the breast.
J Natl Can-
cer Inst
1997;89:1059–1065.
181. Roka S, Rudas M, Taucher S, et al. High nuclear grade and negative
estrogen receptor are significant risk factors for recurrence in DCIS.
Eur J Surg Oncol
2004;30:243–247.
182. Collins LC, Schnitt SJ. HER2 protein overexpression in estrogen re-
ceptor-positive ductal carcinoma
in situ
of the breast: frequency and
implications for tamoxifen therapy.
Mod Pathol
2005;18:615–620.
183. Allred DC, Carlson RW, Berry DA, et al. NCCN task force report:
estrogen receptor and progesterone receptor testing in breast cancer
by immunohistochemistry.
J Natl Compr Cancer Netw
2009;7(Suppl.
6):S1–S21.
184. Cohen DA, Dabbs DJ, Cooper KL, et al. Interobserver agreement
among pathologists for semiquantitative hormone receptor scoring in
breast carcinoma.
Am J Clin Pathol
2012;138:796–802.
185. Walker RA, Hanby A, Pinder SE, et al. Current issues in diagnostic
breast pathology.
J Clin Pathol
2012;65:771–785.
186. Baqai T, Shousha S. Oestrogen receptor negativity as a marker for
high-grade ductal carcinoma
in situ
of the breast.
Histopathology
2003;42:440–447.
187. Bartkova J, Barnes DM, Millis RR, et al. Immunohistochemical dem-
onstration of c-erbB-2 protein in mammary ductal carcinoma
in situ
.
Hum Pathol
1990;21:1164–1167.
188. Gusterson BA, Machin LG, Gullick WJ, et al. Immunohistochemical
distribution of c-erbB-2 in infiltrating and
in situ
breast cancer.
Int J
Cancer
1988;42:842–845.
189. Poller DN, Silverstein MJ, Galea M, et al. Ductal carcinoma
in situ
of the breast: a proposal for a new simplified histological classifica-
tion association between cellular proliferation and c-erbB-2 protein
expression.
Mod Pathol
1994;7:257–262.
190. Schimmelpenning H, Eriksson ET, Pallis L, et al. Immunohistochemi-
cal c-erbB-2 proto-oncogene expression and nuclear DNA content in
human mammary carcinoma
in situ
.
Am J Clin Pathol
1992;97(Suppl.
1):S48–S52.
191. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpres-
sion in breast cancer. Association with comedo-type ductal carcinoma
in situ
and limited prognostic value in stage II breast cancer.
N Engl J
Med
1988;319:1239–1245.
192. Liu E, Thor A, He M, et al. The HER2 (c-erbB-2) oncogene is fre-
quently amplified in
in situ
carcinomas of the breast.
Oncogene
1992;7:1027–1032.
193. Ho GH, Calvano JE, Bisogna M, et al. In microdissected ductal car-
cinoma
in situ
, HER2/neu amplification but not p53 mutation is as-
sociated with comedo and high grade ductal carcinoma
in situ
.
Cancer
2000;89:2153–2160.
194. Barnes DM, Meyer JS, Gonzalez JG, et al. Relationship between
c-erbB-2 immunoreactivity and thymidine labelling index in breast
carcinoma
in situ
.
Breast Cancer Res Treat
1991;18:11–17.
195. Albonico G, Querzoli P, Ferretti S, et al. Biological heterogeneity of
breast carcinoma
in situ
.
Ann NY Acad Sci
1996;784:458–461.
